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Fig 1. Key experiments in the progress of this project 
The project emcompassed three stages, which were represented in three time lines. 
A key experiment (represented as a yellow arrow symbol) in each stage, which has 
been critical in the development of this project, is also shown. 
Key experiment 1. DNA damage-induced Bcl-xL deamidation is inhibited by oncogenic 
LckF505, Fig 7A, Zhao R 2004 
Key experiment 2. Bcl-xL deamidation induced by DNA damage involves up-
regulation of the NHE-1 antiport, Fig 4, Zhao R 2007 
Key experiment 3. Inhibition of the NHE-1/ Bcl-xL deamidation pathway induced by 
DNA damage in Chronic Myelogenous Leukaemia cells, Fig 1, Zhao R 2008 
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SUMMARY 
 
I have been interested in the molecular mechanisms of Haematopoietic malignant 
diseases such as leukaemia and lymphoma, especially those involving oncogenic 
tyrosine kinases. About 30 of the 90 tyrosine kinases in the human genome have 
been implicated in cancer (Blume-Jensen P, 2001). The oncogenic tyrosine kinases 
(OTKs), such as Bcr-Abl (product of chromosomal translocations of two genes bcr 
and abl) in Chronic Myelogenous Leukaemia, and Erythroblastic leukaemia viral 
oncogene homolog 2(Erb-B2) in mammary and other cancers, mediate their 
transforming effects via a diverse array of signalling pathways involved in DNA 
damage, cell survival and cell cycle regulation (Deutsch E, 2001; Skorski T, 2002; 
Kumar R, 1996)  
My work has been centred around the analysis of a mouse cancer model that is 
driven by an oncogenic tyrosine kinase – p56 Lck-F505 expressed on CD45 knock- out 
background (Baker M, 2000). The investigation of this mouse model has revealed 
that oncogenic inhibition of deamidation of the Bcl-xL survival protein plays a critical 
role in protecting thymocytes from DNA-damage induced apoptosis. Cells that would 
normally be eliminated due to accumulating DNA damage are instead preserved with 
an increasing load of double-stranded breaks, leading to genomic instability, 
chromosomal abnormalities and transformation. This work was published in Cancer 
Cell (An oncogenic tyrosine kinase inhibits DNA repair and DNA-damage-induced Bcl-
xL deamidation in T cell transformation. Zhao R, 2004). Following that I have tried to 
elucidate the different roles of the two deamidated species of Bcl-xL in apoptosis, and 
also the molecular mechanisms of DNA damage- induced Bcl-xL deamidation in order 
to understand the inhibition of Bcl-xL deamidation by oncogenic tyrosine kinases. 
Recently I have shown that Bcl-xL deamidation, whereby two critical Asn residues are 
converted to iso-Asp, cripples the ability of the protein to sequester pro-apoptotic 
BH3-only proteins such as Bim and p53- upregulated modulator of apoptosis (PUMA), 
thereby explaining its loss of pro-survival functionality. In vivo, DNA damage causes 
intracellular alkalinisation that is both necessary and sufficient to deamidate Bcl-xL, 
promoting apoptosis: no enzyme is necessary for this process. In pre-tumourigenic 
thymocytes alkalinisation is blocked, so preserving Bcl-xL in its pro-survival mode. 
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Furthermore murine tumours are protected from genotoxic attack by native Bcl-xL, 
but enforced alkalinisation and consequent Bcl-xL deamidation promotes apoptosis. 
This part of work was published in Plos Biology (DNA damage-induced Bcl-xL 
deamidation is mediated by NHE-1 antiport regulated intracellular pH. Zhao R, 
2007). 
 
Through collaboration with Prof AR Green’s research group at the Department of 
Haematology of the University of Cambridge, I have also analysed the Bcl-xL deamidation 
pathway in human myeloproliferative disorders, e.g. Polycythemia vera(PV) and Chronic 
Myelogenous Leukaemia (CML). We found that the oncogenic tyrosine kinases involved in 
these disorders, i.e. Jak2V617F and Bcr-Abl also inhibit the Bcl-xL deamidation pathway in 
DNA damage responses. These findings shed light on potential therapeutic application of 
the Bcl-xL deamidation pathway in human malignancies. This piece of work was recently 
published in the New England Journal of Medicine (Inhibition of the Bcl-xL deamidation 
pathway in myeloproliferative disorders. Zhao R, 2008). 
 
Overall the cited work has led to several important new insights into the molecular 
mechanisms involved in oncogenesis: first, that Bcl-xL deamidation is important in the 
cascade of events leading from DNA damage to apoptosis; second, that oncogenic 
tyrosine kinases inhibit these events in both the murine and human context; third, that 
up-regulation of the NHE-1 antiport and consequent intracellular alkalinisation are 
critical events in this DNA damage-induced cascade leading to apoptosis. In the 
process I have demonstrated the first in vivo mechanism for the deamidation of an 
internal protein Asn. Essentially, a completely new and unexpected signalling pathway 
has been uncovered that seems to pertain to all murine and human haematopoietic cell 
lineages that have been investigated so far. 
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INTRODUCTION 
 
Tyrosine kinases play important roles in cellular function. They normally behave as 
tightly regulated switches in the signal transduction network, however they also 
have the potential to induce oncogenic transformation. 
 
Receptor tyrosine linases (RTKs) such as EGFR and Erb-B2, are composed of an 
extracellular ligand binding domain, a transmembrane domain, and a cytoplasmic 
domain that contains a catalytic kinase core and regulatory sequences (Schlessinger 
j, 2000). RTKs have three general mechanisma to become oncogenic. Firstly, 
genomic rearrangements can generate fused proteins that maintain the kinase in a 
more stable manner; Secondly, gene amplification leads to spontaneous dimerisation 
that stabilizes the kinase; Finaly, some RTKs acquire point mutations that allow them 
to dimerise and stabilize (Blume-Jensen and Hunter, 2001). 
 
Non-receptor tyrosine kinases, such as Src, Lck and Abl, lack extracellular and 
transmembrane domains. Their mechanisms of oncogenic activation are varied. 
Some become constitutively active by fusion to a dimerising partner, while others 
are transformed to onco-proteins by acquiring mutations that disrupt autoinhibitory 
functions (Blume-Jensen and Hunter, 2001). 
 
Oncogenic Tyrosine Kinases (OTKs) are extensively involved in cancer by promoting 
proliferation, invasion, and metastasis. Compared to other onco-proteins, OTKs are 
unique in that they tend to render cells extraordinarily resistant to DNA damage- 
induced apoptosis (Skorski T, 2002). This is demonstrated clinically that cancers that 
express OTKs are usually highly resistant to radio- and chemo- therapy. This clinical 
observation has attracted great interests from clinicians and researchers. The 
resistance, although likely contributed by several mechanisms, has been found 
consistently linked with markedly increased Bcl-xL expression (Kumar R, 1996; 
Amarante-Mendes GP, 1998; Karni R, 1999; Zamo A, 2002). 
 
Bcl-xL is an anti-apoptotic member of the Bcl-2 family. Like Bcl-2, Bcl-xL is believed 
to act by binding and sequestrating BH3-only proteins such as Bim, thereby 
  7 
preventing their pro-apototic interactions with Bax (Cheng EH, 2001; kuwana T, 
2002). Bcl-xL deamidation in response to DNA damage has been recently proposed 
as a critical switch to subvert the pro-survival function of Bcl-xL (Deverman BE, 
2002).  
 
P56Lck is a member of src family tyrosine kinases expressed predominantly in T 
thymocytes. Lck is constitutively located to membranes as a result of modification of 
amino acid residues close to the N-terminus that are sites of myristoylation/ 
palmitoylation (Kabouridis PS, 1997). The N-terminal domain contains a di-cysteine 
motif that is required for association with the CD4 and CD8 coreceptors (Kim PW, 
2003). As with other src-family kinases, the regulation of kinase activity/functionality 
is tightly controlled by conformational changes arising from binding of ligands to the 
SH3 and/or Sh2 domains of the kinases (Holdor AD, 1999; da silva AJ, 1997) and by 
the phosphorylation and dephosphorylation of two critical tyrosine residues (Palacios 
EH, 2004). 
 
Earlier studies (Koretzky GA, 1990; Shiroo M, 1992; Kishihara K, 1993; Byth KF, 
1996; Mee PJ, 1999) have established both positive and negative roles for CD45 in 
controlling the signaling threshold of T-cell antigen receptor (TCR), thereby 
regulating T-cell development (Alexander DR, 2000). Mice expressing active LckF505 
at non- oncogenic levels develop aggressive thymic lymphomas on a CD45 null 
background (Baker M, 2000). CD45 suppresses the tumourigenic potential of the 
kinase by dephosphorylation of the Tyr394 autophosphorylation site (Baker M, 2000; 
Alexander DR, 2000). In CD45-/- thymocytes the kinase is switched to hyperactive 
oncogenic state, resulting in increased resistance to apoptosis. Transformation 
occurs in early CD4-CD8- thymocytes during the process of TCR-β chain 
rearrangement by a recombinase-independent mechanism (Baker M, 2000). 
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Fig 2. A model explaining the interaction between CD45 and various 
phosphorylated sites of p56Lck in CD45+ve and CD45-ve cells. Overall CD45 
acts as both a positive and negative regulator of immune cells function. 
Phosphorylation of Tyr 394 increases p56Lck kinase activity, while phosphorylation of 
Tyr 505 decreases p56Lck kinase activity. 
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CHAPTER 1. CHRONOLOGY OF RESEARCH INTERESTS 
 
1.1.1 Aim and strategy 
 
The first part of my work (Zhao R, 2004) was aiming to elucidate the mechanisms 
involved in the tumourigenesis of CD45-/- LckF505 mice, progeny produced by crossing 
CD45-/- mice and LckF505 mice, instigated by the interesting phenomenon that thymic 
tumours develop in these mice with a 100% penetrance at a quite early age, i.e. 5-
15 weeks. As a contrast, the parental CD45-/- and LckF505 mice do not develop 
tumours during their whole life span.  
 
In an earlier published work from Dr DR Alexander’s group (Baker M, 2000), CD45-/- 
LckF505 mice were phenotypically characterised, with comparisions to wild- type, 
CD45-/- and LckF505 mice in respective of the thymic development and differentiation. 
Higher kinase acitivity of LckF505 was proposed to be the origin of the 
tumourigenesis, however the mechanisms behind this were obscure. 
 
Intrigued by the dramatic tumour development in CD45-/- LckF505 mice, I joined Dr 
Alexander’s group in early 2002, with a medical background in Haemato-oncology, 
hoping to discover the mechanisms entailed by the oncogenic tyrosine kinase LckF505. 
The strategy I used in the study was to analyse the signalling pathways that might 
be involved in the transformation in pre- tumourigenic double- negative (DN) 
thymocytes in relation to LckF505 activity and function.  
 
1.1.2 Kinase activity 
 
Initially, the phosphorylation status and kinase acivity of Lck in CD45-/- LckF505 DN 
thymocytes were analysed in detail. For technical simplicity, I took the advantage of 
having the above mice on Rag-/- background in–house. Rag-/- and Rag-/-CD45-/- 
mice only produce DN thymocytes in their thymus. It is noteworthy that it has been 
shown in the previous study (Baker 2000) that deletion of Rag does not confer any 
changes to the tumour development of CD45-/- LckF505 mice. 
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There are two regulatory sites in wild- type Lck that are important for the kinase 
activity: pTyr- 394 and pTyr- 505, of which pTyr- 394 is a positive regulatory site, 
while pTyr-505 a negative one. CD45 tyrosine phosphatase dephosphorylates both 
sites, keeping Lck activity at an appropriate level and with normal function. However 
in LckF505 Tyr 505 is mutated to Phe, causing a non-regulatory site at the end of Lck.  
CD45 cannot dephosphorylate this site, thus the overall kinase activity in LckF505 is 
lower than in wild- type Lck. However in the absence of CD45, i.e. CD45-/-, LckF505 
has an increased acitivity (Alexander DR, 2000). 
 
Phosphorylation studies on the immunoprecipated Lck protein from Rag-/-CD45-/-
LckF505 DN thymocytes showed an increased phosphorylation of Tyr 394 and 
deceased phosphorylation of Tyr 505 respectively. In vitro kinase assay on the same 
material revealed a 2- 3 fold increase of the kinase activity. The results were 
consistent with previous study and current understandings of the CD45/Lck 
interaction.  Kinase activities in DN thymocytes can be defined as basal (Rag-/-), 
intermediate (Rag-/-CD45-/- or Rag-/-LckF505), or hyperactive (Rag-/-CD45-/- LckF505). 
 
1.1.3 Survival and cell- cycle progression 
 
I considered the commonest signalling pathways that might be involved in 
oncogenesis to start with, i.e. those relating to cellular survival and cell- cycle 
control. Both analyses were performed on gated DN3 and DN4 thymocytes by flow- 
cytometry (FACs). A pool of monocloncal antibodies conjugated with different 
fluorescent dyes allows analysis of DN3/ DN4 subsets with relatively small number of 
cells. 
 
Not surprisingly, Rag-/- thymocytes had a high level of apoptosis and a significant 
growth arrest due to a complete failure of β- selection and lack of pre-TCR mediated 
mitogenic signals. This made Rag-/- mice and its CD45-/- and CD45-/- LckF505 crosses 
most useful in addressing these points. Compared with Rag-/-, Rag-/- CD45-/- 
thymocytes had much less apoptosis– 29.6% compared to 97.3%. While in Rag-/- 
LckF505 and Rag-/- CD45-/- LckF505, the reduction of apoptosis was even more 
significant- both of them had less then 1% of apoptotic cell in their DN3 
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compartment of the thymocytes. Likewise, there were more cells in G2 phase in Rag-
/- CD45-/- than in Rag-/- DN3- 7% compared to 2-4%, whilst in Rag-/- LckF505 and Rag-
/- CD45-/-LckF505, cells in cycle were increased to nearly 30%. 
 
The results described imply that the “intermediate activity” Lck in Rag-/- LckF505 and 
the “hyperactive” Lck in Rag-/- CD45-/- LckF505 have similar effects on the survival and 
cell cycle progression of DN3 thymocytes, though the former is non- oncogenic and 
the latter is oncogenic. This suggests that “intermediate activity” Lck is sufficient for 
keeping the normal survival and cell cycle progression of thymocytes. Since 
“hyperactive” Lck has 2-3 fold increase of the kinase activity compared to 
“intermediate activity” Lck, this begs the question: what is the role of the increased 
kinase activity? There must be something extra conferred by the “hyperactive” Lck 
to transform the thymocytes into cancerous phenotype. 
 
One point to argue here is that the link between kinase activity and apoptosis in DN 
3 thymocytes might be casual. However, as we know LckF505 mice with a higher copy 
number of the transgene, and consequently a higher kinase activity, develop thymic 
lymphoma in a way similar to CD45-/- LckF505 mice.  The evidence demonstrates an 
exquisitely sensitive link between Lck kinase activity and the cellular survival and cell 
cycle progression of DN thymocytes. 
 
1.1.4 DNA repair and genomic instability 
 
It is believed that accumulation of unrepaired double strand breaks (DSBs) can 
cause genomic instability and secondary mutations, which are an important source of 
transformation. Thymocytes are known to be sensitive to genotoxic drugs and 
irradiation. So the DNA repair pathway is another potential candidate to investigate 
(Khanna KK, 2001; Richardson C, 2000). 
 
My first test of the DNA repair pathway was to give same gamma-irradiation to the 
cells, then leave them to repair and measure the repair efficiency at 6h and 24h. 
Irradiated cells were cast into agarose plugs, and proteins were digested with 
proteinase K. DNA containing DSBs were separated from intact DNA by pulse field 
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gel electrophresis (PFGE) technique (Bassing CH, 2003). The results were striking- 
wild- type, CD45-/- and LckF505 DN thymocytes showed similar repair efficiency at 
multiple time points, whilst CD45-/-LckF505 expressed a much more reduced repair of 
DSBs over a 6h or 24h time course.  
 
The results were encouraging in the way that difference between non-oncogenic and 
oncogenic “hyperactive” lck was first revealed. To ensure that this is a true 
phenomenon, the finding was vigorously tested with various methods. 
Phosphorylation of H2AX was measured by western blots and also FACs as 
phosphorylated H2AX (γH2AX) was thought to be a sensitive marker of the DSBs in 
the chromosomes following DNA damage (Bassing CH, 2003; Rogakou EP, 1998). 
The results showed a dramatic increase of γH2AX in untreated CD45-/-LckF505 DN 
thymocytes, suggesting that at basal conditions more DSBs were accumulating in 
the cells, possibly due to the DNA repair deficiency. 
 
DSBs are a source of genomic instability, which can be assessed by karyotype 
analysis with chromosomal painting. This was achieved through collaboration with Dr 
F.T. Yong at the Veterinary School of the University of Cambridge (Yang FT, 1995). 
In pre- tumorigenic DN thymocytes, we detected multiple chromosomal 
abnormalities in 5 Rag-/- CD45-/-LckF505, but no abberations were found in 43 wild- 
type, CD45-/- or LckF505 DN thymocytes. In transformed cell lines from the CD45-/-
LckF505 thymic tumours (Matt cell lines), chromosomal abnormalities were also 
detected. These results provided strong evidence of the genomic instability caused 
by the “hyperactive “ Lck in CD45-/-LckF505 DN thymocytes. 
 
The results together demonstrate a striking correlation between inhibition of DNA 
repair and genomic instability in CD45-/-LckF505 DN thymocytes expressing oncogenic 
Lck. 
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1.1.5 DNA damage- induced apoptosis 
 
Since DNA repair mechanisms were inhibited in CD45-/-LckF505 DN thymocytes, this 
begged the following question: what is keeping these cells with DSBs alive; and 
expanding? I hypothesised whether the apoptotic pathway is disrupted in these cells.   
 
The survival profile was analysed in the cells that were exposed to ionising 
irradiation or etoposide (Fig 4, Zhao R, 2004). The results showed that only in the 
thymocytes expressing oncogenic Lck, was there a powerful survival signal 
protecting the cells from apoptosis. This was a very interesting finding. It seemed 
that a “double whammy” mechanism was functioning behind the transformation of 
these cells. On the one hand, cells were prone to accumulation of DSBs, which were 
possible source of further mutations; on the other hand, the cells were waivered 
from the deadly consequence, so the cells with loads of DSBs could grow, proliferate 
and expand. 
 
1.1.6 Examinaing the survival pathway in CD45-/-LckF505 DN thymocytes in 
DNA damage response 
 
In normal thymocytes, a hallmark of DNA damage is the induction and activation of 
p53 pathway. P53 transcription factor is up-regulated by ATM and ATR 
serine/threonine kinases, which are activated by DNA damage signals, probably 
through γH2AX. P53, as a transcription factor, initiates apoptotic pathway mediated 
by Bax; and cell cycle arrest through p21WAF1 (Sherr CJ, 2002; Vousden KH, 2002).  
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Fig 3. A diagram to show the signalling network involving p53 and 
downstream effectors, and putative mechanisms how hyperactive lck 
affects the various pathways. DNA damage induces phosporylation of p53, which 
stabilises p53 and subsequently drives cells into apoptosis by promoting p21 WAF1 
mediated cell cycle arrest, inducing up-regulation of BH3-only proteins Puma and 
Noxa, and increasing expression of pro-apoptotic protein Bax directly. Hyperactive 
Lck could exert its function by targeting at the various pathways or molecules. 
 
 
I compared the phosphorylation, induction of p53, and the downstream effectors Bax 
and p21 WAF1 between non- oncogenic lck expressing and oncogenic lck expressing 
cells. On finding no significant difference in all the aspects, I concluded that the p53 
machinery was functioning normally in CD45-/-LckF505 DN thymocytes in DNA damage 
response (Fig 2, Zhao R, 2004). 
 
Moving down from p53 to the mitochondria apoptotic machinery, key molecules 
involved in the caspase execution cascade were also examined.  In mammalian cells, 
cytochrome c initiates caspase activation following its release from mitochondria, it 
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also forms an active apoptosome complex with Apaf-1, which activates procaspase-
9, which in turn activates caspase-3.  Active caspase-3 can cleaves poly(ADP-
ribose)polymerase (PARP) to yield an inactive form of PARP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4. A diagram showing various molecules involved in the mitochondrial 
apoptotic pathway and the possible roles that hyperactive Lck plays in this 
signalling network. 
 
 
Starting from PARP I found that the cleavage of PARP was clearly blocked in CD45-/-
LckF505 DN thymocytes that were exposed to DNA damage. This suggested that 
caspase-3 might not be activated properly. Next, I examined caspase-3 status in 
these cells under the same condition, and the results were again striking- caspase-3 
was not cleaved hence not activated, suggesting that the active apoptosome 
complex comprised of cytochrome c and Apaf-1 was not formed. This pointed to the 
possibility of inhibition of cytochrome c release from mitochondria, which had been 
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reported as a critical switch in the initiation of apoptosis (Zou H, 1999; Wang X, 
2001). 
 
In order to measure the quantity of released cytochrome c from mitochondria, 
subcellular fractionation on the cells was carried out and mitochondria (M) and 
cytosol (C) fractions were purified. The quantities of cytochrome c in these two 
fractions were measured by immunoblotting with an anti- cytochrome c antibody.   
In CD45-/-LckF505 DN thymocytes, cytosolic fraction of cytochrome c was greatly 
reduced.  By re-probing the same gel- membrane with a Bax antibody, I found that 
Bax was mostly located in cytosolic fraction instead of mitochondrial fraction in these 
cells.  
 
Bax is a BH3- only protein that translocates from cytosol to mitochondra upon 
apoptotic signals, promoting release of cytochrome c from mitochondria (Gross A, 
1998). A conformational change in Bax precedes its translocation to mitochondria. 
An antibody (6A7 mab) recognises an epitope in its N- terminus that becomes 
exposed during apoptotic signalling (Hsu YT, 1998; Nechushtan A, 1999). I therefore 
examined the conformational status of Bax by utilising this antibody. Naïve Bax was 
immunoprecipated by 6A7 mab, the quantity of which was then measured by 
immunoblotting with a Bax antibody. While in CD45-/-LckF505 DN thymocytes, DNA 
damage induced no confromational change of Bax, it was clearly opposite in wild- 
type, CD45-/- and LckF505 DN thymocytes. 
 
Previous study on mitochondrial apoptosis and Bcl-2 family molecules suggested that 
anti-apoptotic proteins such as Bcl-2 and Bcl-xL bind and sequester BH3-only 
proteins, e.g Bid and Bim, thereby preventing their pro-apoptotic interactions with 
Bax (Cheng EH, 2001; Kuwana T, 2002). As Bcl-2 levels were similar in the DN 
thymocytes from the four mouse lines (previous unpublished work from Dr 
Alexander’s group), I focused my interest on Bcl-xL, which is known to be well- 
expressed in immune cells. In DN thymocytes, Bcl-xL expression was increased 
similarly in both Rag-/- LckF505 and Rag-/- CD45-/-LckF505 mice, compared to controls. 
This still does not explain why tumours develop in (Rag-/-) CD45-/-LckF505 mice, but 
not in (Rag-/-) LckF505 mice.  
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Interestingly Bcl-xL deamidation in response to DNA damage had been proposed as a 
critical switch to subvert the pro-survival function of Bcl-xL (Deverman BE, 2002).  I 
therefore studied the Bcl-xL deamidation status in response to DNA damage in the 
above four mouse lines. I found that Bcl-xL deamidation was inhibited in CD45-/-
LckF505 mice, while it clearly occurred in control mice. This result provided the most 
convincing evidence of how oncogenic LckF505 subverted the apoptotic pathway, 
although the mechanism of how Bcl-xL was deamidated per se was still not clear.  
 
Protein deamidation occurs spontaneously at Asn residues, which are flanked, on the 
α-carboxyl side, by small non-bulky residues, such as Gly, Ala, Ser or Thr (Robinson 
NE, 2001). The nucleophilic attack of the peptidyl nitrogen of the Asn+1 residue onto 
the b-carbonyl carbon of the Asn, leads to the formation of an aspartyl succinimidyl 
intermediate, with the elimination of the ammonia moiety. The aspartyl succinimidyl 
intermediate itself is unstable and its ring can open on either side of the nitrogen 
atom, yielding either a normal peptide or an atypical isopeptide containing a β-linked 
isoaspartyl residue (isoAsp), the latter form being generally predominant (Asward 
DW, 2000). 
 
 
 
Fig 5. Mechanism for deamidation of asparaginyl residues in peptides.  (Fig. 
from Climmino A, 2008) 
(Step 1): the nitrogen of the Asn+1 residue (a Gly in the example) attacks the β-
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carbonyl carbon of the Asn, thus forming the succinimidyl derivative of the peptide 
(ASU) with the ammonia elimination. The ASU ring can open spontaneously on either 
side of the nitrogen atom. In one case the α-aspartyl peptide is formed (Step 2). In 
the other case the β-isoaspartyl peptide does occur (Step 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6. A model integrating the findings on the DNA damage response, cell 
survival and cell- cycle progression in cells with various Lck kinase activity. 
Pathway A refers to signals that are common to both intermediate activity Lck (as in 
DN CD45-/-Lck F505 thymocytes). Pathway B and C are unique to the oncogenic 
hyperactive Lck found in DN CD45-/-Lck F505 thymocytes. (Zhao R, 2007) 
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1.2 How is Bcl-xL deamidated in DNA damage responses?  
 
This is the main question to be answered in the next part of work (Zhao R, 2007). To 
answer this question would be the key to understanding how oncogenic tyrosine 
kinases interact with the Bcl-xL deamidation pathway, and potentially, uncovering 
new strategies in cancer treatment. 
 
1.2.1 Elucidation of the roles of different species of Bcl-xL by in vitro and in 
vivo studies 
 
Initial work from the Weintraub laboratiory suggested that when Asn52 and Asn 66 
were both mutated to Asp, Bcl-xL lost its ability to bind that BH3-only pro-apoptotic 
protein Bim, thereby providing a putative link between DNA damage and apoptosis 
(Deverman BE, 2002). However, a secondary mutation was later identified, which, 
when corrected, enabled the N52D/N66D Bcl-xL to bind Bim, casting doubt on this 
interpretation (Deverman BE, 2003).  As the sequestion of BH3-only proteins by Bcl-
xL was thought to explain its anti-apoptotic function (Cheng EH, 2001), resolution of 
this question was clearly important for establishing a molecular link between DNA 
damage and apoptosis.  
 
To address this point, a series of cellular and biochemical experiments were carried 
out. First of all, whether deamidated forms of Bcl-xL bind to NH3- only proteins 
needed to be elucidated. In the previous work (Zhao R, 2004), Bim could only 
immuno-precipitate Bcl-xL protein from the lysates of CD45-/- LckF505 thymocytes 
which had been treated with etoposide, and also Bcl-xL pulled down much more Bim 
from the CD45-/- LckF505 thymocyte lysates, suggesting that deamidation crippled the 
ability of Bcl-xL to bind Bim. However, Weintraub’s correction showed that mutated 
N52D/N66D Bcl-xL was still able to bind Bim. The discrepancy might have been 
caused by the following reasons: A) The amount of protein Bim may be different 
between CD45-/- LckF505 and other non- tumourigenic mice; B) DNA 
damage/etoposide treatment may induce different amount of Bim; and C) N52-iso 
D/N66-iso D Bcl-xL does not bind Bim, although N52D/N66D Bcl-xL does bind Bim.  
Points A and B were easily eliminated by thorough Bim/ Bcl-xL binding experiments 
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(Fig7B, Zhao R, 2004; Fig 2 A& B, Zhao R, 2007), in which the native and 
deamidated Bcl-xL species were also tested separately for their binding ability with 
Bim, and the results clearly indicated that deamidated Bcl-xL, including both the 
N52D/N66D and N52-iso D/N66-iso D Bcl-xL forms, lost most of its ability to bind 
Bim in vivo. Recombinant Bcl-xL also lost part of its binding to Bim when one site 
was deamidated, and lost most of its binding when two sites were deamidated. I also 
tested the binding of N52D/N66D Bcl-xL form to Bim in thymocytes, which confirmed 
what Weintraub’s laboratory had claimed. 
 
Collectively, the results supported the hypothesis C that N52-iso D/N66-iso D Bcl-xL 
does not bind Bim, although N52D/N66D Bcl-xL does bind Bim. If physiologically N52-
iso D/N66-iso D Bcl-xL exists as the dominant form, it would not be surprising to see 
that deamidated Bcl-xL loses most of its ability to bind BH3-only proteins.  
Consistently, previous literature on protein deamidation showed that when an Asn is 
converted to a mixture of Asp and iso-Asp, the ratio of Asp/iso-Asp is about 1:5 
(Robinson NE, 2001). To confirm this was applicable to Bcl-xL deamidation, it was 
necessary to measure the ratio of Asp/iso-Asp at Asn52 and Asn66. This was 
achieved by Mass Spectrometric analysis. Respective peptides were designed and 
synthesised, which encompass Asn 52/ Asn 66 and their corresponding Asp/ iso-Asp 
forms as identifiers of these species in the same peptides digested from recombinant 
Bcl-xL. The results showed that the ratios of Asp/iso-Asp for Asn 52 and Asn66 were 
10:1 and 5:1, respectively. 
 
Taken together, my results showed that conversion of Bcl-xL Asn 52 and Asn 66 to 
iso-Asp forms, but not Asp counterparts, prevented sequestration of BH3-only 
proteins. In fact deamidation of Bcl-xL to iso-Asp causes greater perturbation of 
protein structure than conversion to Asp (Aritomi M, 1997), presumably explaining 
its loss of BH3-only protein binding ability. 
 
1.2.2 Is Bcl-xL deamidation a consequence of mitochondrial apoptosis? 
 
Whether Bcl-xL deamidation is a cause or a consequence of apoptosis is an obvious 
and important point to elucidate. Clearly if Bcl-xL deamidation is a cause of 
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apoptosis, it will play a more critical role in thymic transformation than being a 
consequence of apoptosis. 
 
This was addressed by using a caspase inhibitor Z-VAD-fmk, which can effectively 
block the occurrence of apoptosis in thymocytes (Fig 1a&b, Zhao R, 2007). In the 
cells treated with etoposide, and with or without Z-VAD-fmk, Bcl-xL deamidation 
occurred at similar levels, suggesting that Bcl-xL deamidation was not a consequence 
of apoptosis. 
 
As Bax and Bak are required in apoptosis mediated by BH3-only proteins, I also 
tested whether depletion of Bax or Bak could block Bcl-xL deamidation. Thymocytes 
were transfected with shRNA for Bax or Bak prior to exposure to DNA damage. As 
shown in Fig 1c (Zhao R, 2007), neither the depletion of Bax or Bak affected the 
occurrence of Bcl-xL deamidation.  
 
1.2.3 The DNA damage- NHE-1 up-regulation- intracellular alkalinisation- 
Bcl-xL deamidation axis 
 
How DNA damage caused Bcl-xL deamidation was a completely unexplored area 
when we started to think about it in early 2006. It was not surprising though as the 
link between DNA damage and Bcl-xL deamidation was just revealed in late 2002 
(Deverman BE, 2002).  
 
It has been known that protein Asn deamidation is accelerated by increased pH in 
vitro. Antiport Sodium-Hydrogen-Exchanger family member 1 (NHE-1) is responsible 
for maintaining the intracellular pH in thymocytes. It seemed to be the only clue to 
follow. The hypothesis would be that DNA damage induces NHE-1 mediated 
intracellular pH (pHi) change. A quick test of this hypothesis was to check whether 
DNA damage could induce any change in NHE-1, which could potentially cause 
intracellular alkalinisation.  
 
Many types of stimuli induce phosphorylation of NHE-1 and thus increase its activity. 
I believed that it might be the same case in DNA damage response. Therefore I tried 
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to check the phosphorylation status of NHE-1 in DNA damaged thymocytes. Using a 
set of anti-phospho antibodies against known phosphorylation sites in NHE-1, I could 
not find altered phophorylation of NHE-1 after DNA damage. However, I noticed on 
the western blots that the NHE-1 expression level was increased after DNA damage. 
It was an interesting finding although there was not much emphasis on the role of 
NHE-1 protein expression level in its function in previous literature.  
 
In parallel I tried to measure the intracellular pH (pHi) before and after DNA 
damage.  Using a pH- sensitive fluorescent dye SNARF-1, pHi can be measured by 
FACS. It was encouraging to find that pHi consistently was increased in DNA 
damaged cells. This increase in pHi was about 0.4-0.5 units, which was both 
necessary and sufficient to cause Bcl-xL deamidation in the cells without exposure to 
DNA damage. These results were achieved by artificially changing the pHi in the cells 
and then examining the Bcl-xL deamidation status.  
 
Whether it was just a casual link between up-regulation of NHE-1 protein level and 
intracellular alkalinisation or whether NHE-1 up-regulation caused intracellular 
alkalinisation needs to be clarified before drawing a conclusion on the mechanism of 
Bcl-xL deamidation. This entailed a series of expeiments. In summary, I had shown 
(Fig 4&5, Zhao R, 2007): 
a) DNA damage– induced Bcl-xL deamidation requires de novo protein synthesis. 
b) DNA damage causes up-regulation of NHE-1 in wild- type but not in CD45-/-
LckF505 thymocytes. 
c) NHE-1 over-expression by retroviral transfection causes intracellular 
alkalinisation and Bcl-xL deamidation. 
d) NHE-1 function blockage by specific inhibitor (DMA) blocks intracellular 
alkalinisation and Bcl-xL deamidation. 
e) NHE-1 gene knock- down by shRNA also blocks intracellular alkalinisation and 
Bcl-xL deamidation. 
 
Collectively the combined evidence strongly supports a model whereby DNA 
damage- induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated 
intracellular alkalinisation. The current model is equally applicable to fully- 
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transformed cells- i.e. CD45-/-LckF505 tumour cells, and human Chronic lymphoblastic 
leukaemia (CLL) cells, though the former express an OTK, the latter do not. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7.  A novel signaling pathway triggered by DNA damage leads to the up-
regulation of the NHE-1 antiport, increased intracellular pH, Bcl-xL 
deamidation, and finally apoptosis. (Fig. from Zhao et al, 2007) 
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1.3 Bcl-xL deamidation pathway in Myeloproliferative Disorders (MPDs) 
 
1.3.1 Why investigate Bcl-xL deamidation pathway in MPDs? 
 
Bcl-xL plays important roles in many tumour types (Amundson SA, 2000), including 
MPDs. My finding on deamidation of Bcl-xL in DNA damage responses therefore have 
potential relevance to cancer therapy, whereby enforced alkalinisation, perhaps by 
amplification of NHE-1 expression, would promote Bcl-xL deamidation, thereby 
triggering apoptosis. 
 
Relevance of Bcl-xL deamidation for human cancers associated with OTKs remained 
unclear, although DNA damaged- induced Bcl-xL deamidation was intact in cell lines 
of osteosarcoma and cervical, bladder and ovarian cancers, and in primary human 
lymphoblastic leukaemia cells (Zhao R, 2007).  
 
MPDs are good candidates for studying Bcl-xL deamidation pathway because, as a 
group of human haemotopoietic malignant diseases, many of them express OTKs. 
Among MPDs, Chronic Myeloid Leukaemia (CML) and Polycythemia vera (PV) are the 
two seeing most significant breakthroughs in the understanding of their pathological 
mechanisms. They are associated with the BCR-ABL fusion tyrosine kinase and the 
Janus tyrosine kinase 2 (JAK2) mutation V617F, respectively.  Both disorders initially 
usually present with chronic diseases, but carry a risk of progression to blastic phase 
resembling acute leukaemia that resists further therapy (Goldman JM, 2003; 
Campbell PJ, 2006). 
 
Bcl-xL has been shown to be up-regulated in patients with CML and PV and is thought 
to inhibit apoptosis. BCR-ABL protein expression is associated with a reduced 
apoptotic response to genotoxic drugs. Moreover, quiescent CML stem cells, thought 
to be responsible for residual disease, are resistant to apoptosis that tyrosine kinase 
inhibitors induce. Collectively the combined results suggested there might be an 
undiscovered link between Tyrosine kinases BCR-ABL and Jak2V617F and the 
resistance to DNA damage- induced apoptosis in CML and PV patient myeloid cells. 
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1.3.2 Patients’ sample collection and cell purification 
 
Access to human samples was made possible by collaboration with Prof. AR Green’s 
research group at the Department of Haematology, Addenbrooks Hospital, University 
of Cambridge. The study was approved by the Cambridge and Eastern Region ethics 
committee. All patients involved provided written informed consent.  
 
Cells of myeloid or lymphoid lineage were purified from peripheral blood samples. 
The process involves using density separation through centrifugation, followed by 
immunological targeting to cell surface markers combined with flow cytometry. 
Unlike using thymocytes from established mouse lines, human samples were 
precious in terms of how many cells were available and when they were available. 
This responsibility proved challenging but satisfying, as it constituted a particularly 
good model system upon which to work. 
 
1.3.3 Bcl-xL deamidation pathway is inhibited in CML myeloid cells 
 
Purified myeloid/ granulocytes from normal subjects and CML patients were treated 
with etoposide or exposed to γ-irradiation. Then every step in the Bcl-xL deamidation 
pathway was examined, i.e. NHE-1 expression level change, intracellular pH 
alteration, Bcl-xL deamidation status and apoptosis of the cells. Results from 6 
normal controls and 10 CML patients consistently showed that the Bcl-xL deamidation 
pathway in DNA damage responses was intact in normal cells while inhibited in CML 
cells.  
 
T cells purified from the same CML patient samples, as good internal controls, 
showed no effect on the Bcl-xL deamidation pathway (Suppl Fig 3, Zhao R, 2008). 
The same CML myeloid cells were subjected to a series of  ‘forced alkalinisation’ 
experiments, where cells were cultured in alkaline medium i.e. pH>8. I found that 
the resistance to Bcl-xL deamidation was overcome in these cells. It suggested that 
the inhibition by Bcr-Abl was at the step of up-regulation NHE-1, which was same as 
in p56LckF505. 
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The dysfunction of Bcl-xL deamidation pathway in CML cells was further examined 
aiming to identify the critical steps responsible. CML cells were transfected with a 
retroviral vector carrying NHE-1 cDNA in order to over- express NHE-1 in CML cells. 
These cells not only became alkalinised intracellularly, but also had more Bcl-xL 
protein deamidated and subsequently apoptosed. 
 
1.3.4 BCR-ABL inhibitor Imatinib reverses the inhibition of Bcl-xL 
deamidation pathway in CML myeloid cells  
 
Imatinib is a very effective BCR-ABL inhibitor. Its application in treating CML patients 
has been so successful that most CML patients will achieve complete regression. 
However, a small proportion of CML patients develop resistance to Imatinib by point 
mutation of the BCR-ABL kinase domain. In my experiments Imatinib- sensitive CML 
cells were either pre-treated with Imatinib or not, then were exposed to 
etoposide/irradiation. NHE-1 expression level and Bcl-xL deamidation status were 
examined subsequently. The results were clear that Imatinib completely reversed 
the inhibition of Bcl-xL deamidation in these CML cells. 
 
1.3.5 Imatinib does not reverse the inhibition of Bcl-xL deamidation pathway 
in Imatinib- resistant CML cells that carry an E255V mutation in the BCR-
ABL kinase domain 
 
Although Imatinib is known to be a very specific BCR-ABL kinase inhibitior, it also 
inhibits a few other kinases. Strictly speaking, the above reversion of the inhibition 
of Bcl-xL deamidation pathway might possibly be due to the other effects of Imatinib.  
 
At this point I managed to obtain an imatinib- resistant CML sample, which carried 
an E225V mutation in the BCR-ABL kinase domain. The same experiments were 
performed with this sample. Strikingly, the reversion of the Bcl-xL deamidation 
pathway did not occur. Furthermore, the same cells were transfected with a NHE-1 
vector using a Nucleofector kit. NHE-1 was over-expressed in these cells, which 
subsequently caused intracellular alkalinisation and Bcl-xL deamidation. 
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This series of experiments involving Imatinib sensitive and resistant CML cells 
strongly support the critical role of BCR-ABL in the inhibition of Bcl-xL deamidation 
pathway in CML. 
 
1.3.6 Bcl-xL deamidation pathway is inhibited by Jak2V617F in PV myeloid 
cells 
 
Likewise, in a series of similar experiments, Jak2V617F in PV myeloid cells exhibited its 
role in blocking the DNA damage- induced NHE-1/Bcl-xL deamidation pathway, i.e. 
NHE-1 up-regulation, intracellular alkalinisation, Bcl-xL deamidation and apoptosis. T 
cells purified from the same PV patient samples, as good internal controls, showed 
no effect on the Bcl-xL deamidation pathway (suppl Fig 3, Zhao R, 2008). 
 
1.3.7 Jak 2 inhibitor reverses the inhibition of Bcl-xL deamidation pathway 
in PV myeloid cells 
 
Whilst there were no established specific Jak2 inhibitors available, three inhibitors 
with different sensitivity and specificity were used. Jak inhibitor 1 (Calbiochem) is a 
pan- inhibitor of Jak, TG101209 (Targagen) and AT9283 (Astex) are inhibitors 
currently in clinical trials, which have been shown in cellular experiments inhibiting 
Jak2 (Prof AR Green unpublished data). 
 
Surprisingly all three Jak2 inhibitors all showed significant effects in inhibiting the 
Bcl-xL deamidation pathway, although one of them was apparently more potent than 
others. Similarly the PV myeloid cells were subjected to ‘forced alkalinisation’ 
experiments. The resistance to Bcl-xL deamidation was also overcome in these cells 
suggesting that the inhibition by Jak2V617F is at the step of up-regulation NHE-1, 
which is same as p56LckF505Y and Bcr-Abl. 
 
1.3.8 Bcl-xL deamidation pathway in Jak2V617F-positive Idiopathic 
Myelofibrosis (IMF)  
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IMF represents a sub- group of diseases in myeloproliferative disorders. Some IMF 
patients carry Jak2V617F mutations, wherease others do not. Luckily I was able to 
obtain two Jak2V617F-positive and two Jak2V617F-negative IMF patient samples to 
study the Bcl-xL deamidation pathway. The results were very encouraging- the Bcl-xL 
deamidation pathway was inhibited in Jak2V617F–positive IMF patient cells. This again 
supports the correlation of Jak2V617F and the blockage of DNA damage- induced Bcl-
xL deamidation pathway in myeloproliferative disorders.  
 
1.4 Tyrosine kinases in other haematological malignancies- potential 
research interests and therapeutic targets? 
 
Eight cancer cell lines were also studied, representing different haematologic cancers 
associated with distinct molecular mechanisms. Among these, K562 expresses Bcr-
Abl, HEL expresses Jak2V617F in Jak2V617F and Karpas 299 expresses NPM-ALK, a 
tyrosine kinase; Daudi expresses c-myc, DU528 expresses Tal1, JVM2 expresses 
cyclin D1, OPM2 expresses FGFR3 and DOHH2 expresses Bcl-2.  
 
While demonstrated again that Bcr-Abl and Jak2V617F inhibit the NHE-1/Bcl-xL 
deamidation pathway, none of the other onco-proteins do, including tyrosine kinase 
NPM-ALK. So the inhibition of Bcl-xL deamidation pathway is not a general feature of 
haematologic cancers and is only mediated by a sub- group of tyrosine kinases or is 
dependent on a particular cellular context. 
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CHAPTER 2. CRITIQUES/REFLECTION  
 
2.1. Asn 52/66 issues 
 
Original work from Weintraub laboratory suggested that deamidated Bcl-xL does not 
bind to BH3- only protein Bim. However, this result was later withdrawn due to the 
identification of a secondary mutation in the original DNA construct used in the 
experiments. When the secondary mutation was corrected deamidated Bcl-xL did 
bind to Bim (Deverman BE, 2003). 
 
Interestingly, I found that whereas the ability of Bcl-xL to bind Bim was ablated in 
control thymocytes exposed to DNA damage, it was strikingly retained in CD45-/-
LckF505 thymocytes, tightly correlating with the resistance to Bcl-xL deamidation 
noted in these cells.  
 
These findings cast doubt on the model that Bcl-xL triggers apoptosis because the 
sequestration of BH3-only proteins by Bcl-xL is thought to explain its anti-apoptotic 
function. Resolution of this question is clearly important for establishing a molecular 
link between DNA damage and apoptosis.  So at an early stage of my project I 
carried out a series of cellular and biochemical experiments to address this key 
point, such as, immunoprecipitation of Bim from cell lysates with a Bcl-xL antibody or 
the other way around, and measuring the precipitated proteins by western blots. 
Recombinant His-tagged Bcl-xL was exposed to alkaline conditions to cause partial 
deamidation and separated by anion exchange chromatography into purified native, 
singly deamidated and doubly deamidated Bcl-xL proteins, and these different 
species of Bcl-xL bound with endogenous Bim in a completely different manner, i.e. 
native Bcl-xL has a maximum binding ability, doubly deamidated Bcl-xL does not bind 
with Bim at all, while singly deamidated Bcl-xL lies in between.  And interestingly, 
both the Bcl-xL N52A/N66A and N52D/N66D mutants maintain the complete binding 
ability with BH3-only proteins as the native Bcl-xL. Given that most asparagines 
deamidate to iso-aspartate forms at physiological conditions in cells, it is reasonable 
to suggest that the change from asparagine to aspartate does not affect the binding 
with BH3-only proteins, but the conversion from asparagine to iso-asparatate does.  
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This speculation was also validated by a definitive experiment, which nevertheless, 
was to prove an established view, was however, critical in the interpretation of the 
mechanism of Bcl-xL deamidation.  Aspartate and iso-aspartate species of Bcl-xL 
were separated from naturally occurred Bcl-xL mixture by LC-MS chromatography 
respectively, and their quantities were compared, which confirm that more than 90% 
of asparagines in Bcl-xL convert to iso-aspartates, but not aspartates. 
 
2.2. Global effects of alkalinisation 
 
One argument about the NHE-1/ Bcl-xL deamidation pathway is that intracellular 
alkalinisation can possibly cause deamidation of other proteins. What roles do they 
play in apoptosis and transformation?  This is a fair argument. I have been trying to 
address this question in different ways. The most critical evidence is that when Bcl-xL 
is mutated to N52A/N66A mutant, a constitutively native form, enforced intracellular 
alkalinisation does not increase apoptosis. So although the global effect of 
alkalinisation is inevitably present, its role in apoptosis might be negligible. 
 
The possibility of pH manipulation as a means to cancer therapy has in the past 
attracted intermittent interest. The pioneering work of Warberg established that 
tumours display acidic extracellular pH (Warberg O, 1930), although half a century 
later it was established that the intracellular pH of tumours is comparable with 
normal cells (Griffiths JR, 1991). My findings suggest that strategies for pH 
manipulation in anti-neoplastic therapy should continue to receive attention, albeit 
for reasons different from those envisaged by Warberg. 
 
2.3. Protein modification in signal transduction 
 
Proteins are frequently modified in signal transduction. Modification of proteins 
confers new function to the molecules and often the proteins with altered function 
play critical roles in signalling networks. Phosphorylation, methylation, sumoylation 
etc. have attracted more research attention and indeed demonstrated their 
importance in protein and cellular function. Deamidation, though universally 
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occurring in all proteins, has only recently been shown being involved in rapid 
physiological events, i.e. signal transduction of Bcl-xL. Is it just an individual 
phenomenon, or revealing a completely new type of protein modification with 
physiological significance, needs to be elucidated.  
 
A number of cell stress conditions have recently been linked to protein deamidation.  
Oxidative conditions have been considered as a way through which protein 
deamidation is facilitated. Protein Isoaspartate Methyltransferase (PIMT) may be 
able to mediate protection from apoptosis induced by Bax in a neuronal cell line by 
catalyzing protein methyl esterification (Cimmino A, 2008). PIMT has been shown to 
be able to prevent isoaspartate accumulation in the Eukaryotic Initiator Factor 
Binding Protein 2 (4E-BP2), an important factor in learning and memory, in the brain 
(Bidinosti M, 2010). Deamidation has also been involved in ubiquitination and 
ubiquitin- dependent degradation of peptides (Cui J, 2010) 
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CHAPTER 3. CONCLUSION AND FUTURE WORK  
 
Protein deamidation is a naturally occurring process, which increases protein 
turnover, and has been proposed as a molecular timer of biological events (Robinson 
NE, 2001). However, the significance of protein deamidation to the cell has never 
been firmly established. It has been suggested, in respect to the regulation of DNA 
damage-induced apoptosis, Bcl-xL deamidation may serve as a chronometric buffer, 
affording the cell time to reverse low-level genotoxic stress-induced events 
(Deverman BE, 2002). Rapid deamidation of Bcl-xL induced by DNA damage 
indicates that the deamidation ”clock” is a dynamic process that can be regulated in 
vivo by biological events (Zhao R, 2007).  
 
Bcl-xL is an important pro-survival protein whose potency is emphasised by its 
protection of a wide range of tumour cells from genotoxic attack (Amarante-Mendes 
et al., 1998; Amundson et al., 2000; Brumatti et al., 2003). The role of Bcl-xL 
deamidation in the transformation of OTK- expressing cells is particularly critical, as 
it explains how these cells gain their survival advantage under extreme conditions- 
i.e. cytotoxic drugs or gamma-radiation. It also explains why these cells, once they 
become cancerous, are notoriously resistant to chemo- or radiotherapy.  
 
It is interesting that a few OTKs inhibit the NHE-1/Bcl-xL deamidation pathway, 
wherease others do not. Further study is needed given the vast number of OTKs 
involved in human cancer. Finally whether it is applicable to target at the NHE-1/Bcl-
xL deamidation pathway warrants attention, although variances are predictable due 
to biological/cellular complexity. 
 
Future work 
 
There are a number of lines of work that need to be done in order to understand the 
relationship between OTKs and the NHE-1/Bcl-xL deamidation pathway, and 
hopefully, to be able to manipulate the components involved in oncogeneis to 
generate potential new cancer therapy. 
 
  33 
The hypothesis that inhibition of DNA-damage induced alkalinisation and Bcl-xL 
deamidation causes transformation needs to be vigorously tested. 
 
Firstly, what is the role of NHE-1 in tumourigenesis? This can be achieved by 
generating new transgenic/ knock-in mouse models based on the CD45-/-p56lck-Y505F 
mouse model. If we can express NHE-1 in the CD45-/-p56lck-Y505F mouse in a 
regulatory manner, i.e. tetracycline- controlled expression, then we can observe 
whether NHE-1 up-regulation can prevent tumour development, and, whether NHE- 
down- regulation can induce tumour relapse. Tumour growth monitoring can be 
achieved by using the immunoflurescence/illuminence technique, which itself will 
require careful design of the molecular tags. 
 
Secondly, is prevention of Bcl-xL deamidation sufficient for transformation? Blockade 
of the Bcl-xL deamidation pathway plays an important role in the transformation 
driven by three OTKs - LckY505F, Bcr-abl and Jak2V617F. Whether Bcl-xL deamidation is 
directly involved in the transformation process needs to be validated in vivo. One 
way of doing this is to generate a mouse model with the two asparigines in Bcl-xL 
replaced by Alanines so that they are not able to deamidate, i.e. a mouse model with 
a constitutively “native” Bcl-xL. If this mouse is crossed with an OTK model, i.e. 
CD45-/-p56lck-Y505F, then the role of Bcl-xL deamidation can be tested by subjecting 
the live mice to DNA damage and monitor tumour occurrence etc. 
 
How NHE-1 expression is regulated following DNA damage also needs to be studied. 
This is still a mystery so far. NHE-1 expression and modification have been studied in 
the context of various stimuli, such as growth factors, cytokines, homeostasis, etc. 
But the link between DNA damage and NHE-1 has not been paid much attention, 
probably due to the fact that NHE-1, as an antiport, was mainly investigated in 
cardiovascular diseases (Fliegel L, 2001) 
 
Lacking this important information, it is impossible to understand how the oncogenic 
tyrosine kinases (e.g. LckY505F, Bcr-abl and Jak2V617F) carry out their abnormal 
function and drive the transformation of the cells. The increased expression level of 
NHE-1 could be caused at various stages: 1) messenger RNA level - transcriptional 
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or mRNA stability, and 2) protein level – translational or protein stability.  My 
preliminary data show that DNA damage triggers increased NHE-1 mRNA levels in 
wild-type thymocytes, but not in the thymocytes transformed by hyper- active 
LckF505 (Appendix Fig 7). This suggests that the up-regulation of NHE-1 in response 
to DNA damage is caused at least in part by increased mRNA. NHE-1 antiport is a 
well- characterised protein, and regulation of NHE-1 expression in response to 
multiple stimuli other than DNA- damage has been extensively investigated (Dyck 
JR, 1995; Yang W, 1996). These investigations have established that NHE-1 
expression is mainly regulated by transcription, and a number of transcription 
binding sites for these other stimuli have been identified in the promoter region of 
the NHE-1. So it is not premature to hypothesise that in DNA damaged cells NHE-1 
increases expression level by transcriptional mechanism. 
 
There is plenty to discover in this completely untouched area- such as, the 
responsive elements in NHE- promoter and the transcription factors that are critical 
in initiating the transcription in response to DNA damage signals; the inhibitory 
mechanisms employed by the OTKs to block the transcription, etc. 
 
Thirdly, but not lastly, any other proteins that could be deamidated by the DNA 
damage induced intracellular alkalinisation?  
 
A large percentage of proteins deamidate to a substantial extent during their 
biological life times (Nordhoff E, 1999). Among these spontaneous protein 
deamidation processes, Bcl-xL deamidation is the first example of rapid protein 
deamidation triggered by genotoxic stress, and playing a central role in the 
regulation of biological process. Other protein deamidation processes might also be 
promoted following DNA damage. There could be a plenary of molecules with various 
roles in cellular physiology that are regulated by deamidation. 
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APPENDIX  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 8. Quantitative RT-PCR results showing the NHE-1 mRNA level (mean values 
± SD, n=3) in C57BL/6 and CD45-/- LckF505 thymocytes at time 0, 3, 6, 9 h of 
etoposide treatment. The RT-PCR were run on Bio-Rad Chromo4, and NHE-1 mRNA 
is normalised for actin mRNA.  
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